- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03497130
The Role of Skin Care Regimen in Skin Health
Study Overview
Detailed Description
Dry skin is a common phenomenon and can dramatically decrease a person's quality of life as well as contribute to a wide variety of skin diseases. Skin care products hydrate the skin and breaks the dry skin cycle. While there is extensive evidence of benefits of using mild cleansers and moisturizers, much of the previous studies are limited to the effects of single cleanser or moisturizer.
In this study, the investigators are going to enroll up to 100 people over the age of 18 with dry, itchy skin and they will be split into 2 groups. Participants will be randomly assigned to skin care regimen group (approximately 75% of total enrolled) and control group (approximately 25% of total enrolled). All evaluation include clinical assessments, subject questionnaires and photography will be conducted similarly in both groups.
Analysis will include paired and unpaired t-tests with two-tailed p-values. Values obtained at baseline, in middle of the study and after completing the study will be compared. The difference of measure values will be compared between application group and control group.
The moisturizing lotion and wash are generally very well tolerated.Rarely, they can induce a burning sensation, dryness, skin irritation, erythema, stinging, sensitization, and dermatitis. Risk events, problems, and deviations will be reported by the PI directly to the Institutional Review Boards.
The investigators hope to learn the importance of regular skin care regimen in improving dry skin and overall skin health.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Cutaneous Translational Research Program
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be over the age of 18 years old with dry, itchy skin;
- Participant must be willing to comply with the requirements of the protocol;
- Participant must have the ability to understand and communicate with the investigator;
- Participant must provide informed consent.
Exclusion Criteria:
- Subjects who are unable to provide informed consent;
- Subjects who are unable to refrain from swimming or hot tub use throughout the study duration
- Subject with significant medical history or current skin diseases that the investigator feels is not safe for study participation;
- Subjects who have been treated with systemic retinoids or steroids within the past month prior to entry to the study;
- Subjects who have been treated with topical steroids, retinoids or other topical drugs within 2 weeks prior to entry to the study;
- Recently treated or current skin diseases that would affect clinical evaluation;
- Subjects who self-report that they are pregnant or nursing;
- Patients with history of investigational drug use in the 30 days prior to entry into the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: regimen group
After 1 week washout period using provided Dove® Soap without any moisturizer, participants in the skin care regimen group will receive Vaseline® Moisturizer, Dove® Soap, and application log.
These participants will be asked to apply the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks.
All applications should be reported in the application log by the participants.
A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use.
|
These participants will be asked to apply skin care regimen, the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks.
|
No Intervention: control group
After 1 week washout period using provided Dove® Soap without any moisturizer, Individuals in the control group will continue with the provided Dove® Soap for 2 weeks. All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Total Clinical Score (TCS) Between the Final Visit and Baseline
Time Frame: Baseline and 3 weeks
|
Evaluated by blinded investigator, consists of three section; erythema (0=no erythema; 4=fiery red with oedema), scaling(0=no scaling; 3=severe scaling), and fissures scored 0-3 (0=no fissure; 3=wide cracks with hemorrhage) yield total between 0 and 10.
The evaluation will be done for four sites: both lower legs and both forearms.Total Body Score (TCS) is the sum of three symptoms, i.e., erythema (0 = no erythema, 1 = slight erythema, 2 = moderate uniform redness, 3 = intense redness, 4 = fiery red with edema), scaling (0 = no scaling, 1 = fine scaling, 2 = moderate scaling, 3 = severe scaling with large flakes), and fissure (0 = no crack/fissure, 1 = fine cracks, 2 = single or multiple broader fissures, 3 = wide cracks with hemorrhage or exudation).
Thus, the TCS could range from 0 to 10, with the higher scores representing more severe condition.
|
Baseline and 3 weeks
|
Change in Visual Dryness 5-point Severity Score for Total Body Score Between the Final Visit and the Baseline
Time Frame: Baseline and 3 weeks
|
Visual Dryness Severity (VDS) was evaluated by blinded investigator, scored on a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe, yield total between 0 and 4. The evaluation will be done for four sites: both lower legs and both forearms.
Total body score is the sum of the four sites, ranging from 0 to 16 with the higher scores representing more severe dryness.
|
Baseline and 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Frequency of Itchy-specific Quality-of-life (ItchyQoL) Score Between the Final Visit and Baseline
Time Frame: Baseline and 3 weeks
|
Self-reported itchy related quality of life questions.
Total 22 items and each item is scored as frequency.
Frequency items are scored on scale of 1-5 (1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = all the time) by four measures : Symptom with score range (6-30), Function with score range (7-35), Emotion with score range(9-45) and Overall with score range(22-110).
The higher score represents more severe condition.
|
Baseline and 3 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anna Chien, MD, Johns Hopkins University
Publications and helpful links
General Publications
- Kawada C, Yoshida T, Yoshida H, Matsuoka R, Sakamoto W, Odanaka W, Sato T, Yamasaki T, Kanemitsu T, Masuda Y, Urushibata O. Ingested hyaluronan moisturizes dry skin. Nutr J. 2014 Jul 11;13:70. doi: 10.1186/1475-2891-13-70.
- Feng L, Chandar P, Lu N, Vincent C, Bajor J, McGuiness H. Characteristic differences in barrier and hygroscopic properties between normal and cosmetic dry skin. II. Depth profile of natural moisturizing factor and cohesivity. Int J Cosmet Sci. 2014 Jun;36(3):231-8. doi: 10.1111/ics.12118. Epub 2014 Mar 29.
- Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatol Ther. 2004;17 Suppl 1:43-8. doi: 10.1111/j.1396-0296.2004.04s1005.x.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00165140
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Itching
-
Orion Corporation, Orion PharmaCompleted
-
Dr. Soliman Fakeeh HospitalCompleted
-
Pierre Fabre Medical DevicesCompleted
-
Ecobrands, Ltd.Completed
-
United States Army Institute of Surgical ResearchCompleted
-
Dove Medical Press LtdThe Affiliated Hospital of Qingdao UniversityActive, not recruiting
-
Dove Medical Press LtdThe Affiliated Hospital of Qingdao UniversityActive, not recruitingItching | Genital InflammationChina
-
University Hospital, BrestRecruitingTolerance | Biopsy Site ItchingFrance
-
Swiss-American Products, IncMcGill University; Hospital de readaptation Villa Medica; Precision ConsultingCompletedPruritus | Itching | Burn PruritusCanada
-
Meir Medical CenterYigal Allon Kinneret Limnological LaboratoryUnknown
Clinical Trials on skin care regimen
-
Burt's Bees Inc.Dermatology Consulting Services, High Point NCCompletedRosaceaUnited States
-
HiPP GmbH & Co. Vertrieb KGCharite University, Berlin, GermanyCompleted
-
University of the PhilippinesCalmoseptine, Inc.CompletedIncontinence Associated DermatitisPhilippines
-
Integrative Skin Science and ResearchCodex Beauty CorporationNot yet recruitingAcne VulgarisUnited States
-
University of HullProcter and GambleCompletedNon-filarial Elephantiasis
-
Cynosure, Inc.CompletedMelasmaUnited States
-
London School of Hygiene and Tropical MedicineMRC/UVRI and LSHTM Uganda Research Unit; Makerere UniversityCompletedPreterm Infant | Hypothermia, Newborn | Kangaroo Mother Care | Death; NeonatalUganda
-
University of MiamiAllergan Sales, LLCCompleted
-
Björn Westrup, MD PhDUniversity of BergenTerminated
-
Fatih UniversityUnknownImmaturity | Oral Intolerance | Postnatal AdaptationTurkey